Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06216665 · ClinicalTrials.gov registry record · NA
Effect of Pulsatile Hormone Administration on Insulin Action
A NA study of Insulin Sensitivity, sponsored by Pennington Biomedical Research Center.
- Recruiting
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06216665: Recruiting NA study of Insulin Sensitivity, sponsored by Pennington Biomedical Research Center.
NCT06216665 is a NA study of Insulin Sensitivity that is actively recruiting participants, run by Pennington Biomedical Research Center. The registered enrollment target is 12 participants, below the 72-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06216665, a NA study of Insulin Sensitivity, is actively recruiting participants, sponsored by Pennington Biomedical Research Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. Given the fluctuations in insulin concentrations, oscillations enhance precision of control. The hyperinsulinemic euglycemic clamp test (clamp) involves a continuous infusion of insulin and is the gold standard for measuring insulin sensitivity. In this study, insulin sensitivity measured using the standard clamp will be compared with a clamp in which the same total amount of insulin as the standard clamp is infused every five minutes instead of continuously.
Primary Outcome
Glucose infusion rate during the hyperinsulinemic euglycemic clamp test
Conditions Studied
Interventions
- OTHER Continuous Insulin administration during hyperinsulinemic euglycemic clamp test
- OTHER Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2025-12 |
| Phase | NA |
What NCT06216665 shows while recruiting
NCT06216665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 72-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 2 interventions - of which Continuous Insulin administration during hyperinsulinemic euglycemic clamp test is the first listed.
NCT06216665 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT06216665 about?
NCT06216665 is a clinical study titled "Effect of Pulsatile Hormone Administration on Insulin Action". In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. Given the fluctuations in insulin concentrations, oscillations enhance precision of control. The hyperinsulinemic euglycemic cl...
What is the current status of trial NCT06216665?
This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2024-03-04. Estimated completion is 2025-12.
What conditions does trial NCT06216665 study?
This clinical trial studies the following conditions: Insulin Sensitivity.
What interventions are being tested in trial NCT06216665?
The interventions under investigation include: Continuous Insulin administration during hyperinsulinemic euglycemic clamp test (OTHER), Pulsatile Insulin administration during hyperinsulinemic euglycemic clamp test (OTHER).
Who is sponsoring clinical trial NCT06216665?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06216665 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Sensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06216665's enrollment target sits among peer trials
12 27th of 29 higher than 3 of 29 other Insulin Sensitivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Sensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Countermeasures to Circadian Misalignment
RECRUITING · NA
-
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
RECRUITING · NA
-
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
RECRUITING · NA
-
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI